Markets

Dr. Reddy's Re-launches OTC Famotidine Tablets In U.S. - Quick Facts

(RTTNews) - Dr. Reddy's Laboratories Ltd. (DRREDDY, RDY) announced Tuesday the re-launch of over-the-counter or OTC Famotidine Tablets USP, 10 mg and 20 mg, in the U.S. market.

OTC Famotidine Tablets are the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC, approved by the U.S. Food and Drug Administration.

OTC Famotidine Tablets are acid reducers that prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages. They are available in multiple pack sizes to allow consumers a variety of purchasing options.

The Pepcid AC brand, by Johnson & Johnson, and generic had U.S. sales of approximately $211 million for the most recent twelve months ended in August 2020.

Marc Kikuchi, CEO, North America Generics, Dr. Reddy's said, "This launch will help us fulfil an important therapy gap created in Antacids market due to Ranitidine withdrawal."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RDY

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More